Known targets — ChEMBL curated mechanism
KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 0.72 |
| ▸ | TSHR | P16473 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.72 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanidine SCHEMBL28700657 | 1.00 | DNM1 (0.72) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Dodecylamine SCHEMBL27696549 | 1.00 | DNM1 (0.72) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Octadecylamine SCHEMBL28250639 | 1.00 | DNM1 (0.72) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Butylamine SCHEMBL27571619 | 0.88 | — | — | |
| Guanidine SCHEMBL27317151 | 0.88 | SPHK2 (0.68) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Dodecylamine SCHEMBL25308253 | 0.85 | DNM1 (0.87) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Methyl Alcohol SCHEMBL28365635 | 0.85 | — | — | |
| Dodecylamine SCHEMBL30648425 | 0.85 | DNM1 (0.87) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Methyl Alcohol SCHEMBL3390948 | 0.85 | DNM1 (0.87) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Tetradecylamine SCHEMBL17238770 | 0.85 | DNM1 (0.87) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766412-B2 | Methods of treating or alleviating adenylosuccinatelyase (ADSL) deficiency using spermidine or a pharmaceutically acceptable salt of spermidine | GENEHEAL BIOTECHNOLOGY CO., LTD. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| EP-3524614-A1 | COMPOUNDS WEAKENING SAICAR SYNTHASE ACTIVITY, AND APPLICATIONS | Geneheal Biotechnology Co., Ltd. (CN) | 2019-08-14 | — | — | EP | disclosed |
| US-20190209499-A1 | COMPOUNDS WEAKENING SAICAR SYNTHETASE ACTIVITY AND APPLICATIONS | GENEHEAL BIOTECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209499-A1 | COMPOUNDS WEAKENING SAICAR SYNTHETASE ACTIVITY AND APPLICATIONS | ADSL, ADSS2, ACACB | DNM1 3917/4885TSHR 3229/4885MEN1 4234/4885 |
| US-11766412-B2 | Methods of treating or alleviating adenylosuccinatelyase (ADSL) deficiency using spermidine or a pharmaceutically acceptable salt of spermidine | ADSL, ADSS2, SRM | DNM1 2627/4885TSHR 2080/4885MEN1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.